Prognostic value of somatostatin receptor subtype 2 expression in colorectal cancer.

Abstract

The clinical relevance of the somatostatin receptor subtype 2 (sst2) is well defined in neuroendocrine tumors but it is still a matter of debate whether its expression may have a role also in other tumors not arising from the neuroectoderm. We investigated the prognostic value of the expression levels of sst2 mRNA in a consistent group of patients affected by colorectal cancer. Survival analysis of cancer-related death showed that patients with a high sst2 mRNA expression had an unfavourable outcome (p=0.037) and a significantly shorter disease-free survival (p=0.008). Surprisingly, our findings suggest that sst2 gene overexpression is a feature of colorectal tumors that have a negative outlook; in addition, it may allow additional insight into conventional therapeutic approaches for more aggressive tumors, whose prognosis needs to be improved.

Statistics

05001000150020132014201520162017
Citations per Year

270 Citations

Semantic Scholar estimates that this publication has 270 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Raggi2005PrognosticVO, title={Prognostic value of somatostatin receptor subtype 2 expression in colorectal cancer.}, author={Claudia Casini Raggi and F. Cianchi and Rosa Valanzano and Michela Cameron Smith and Mario Serio and Mario Maggi and Claudio Orlando}, journal={Regulatory peptides}, year={2005}, volume={132 1-3}, pages={23-6} }